Disease · MONDO_0005271

allergic disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. allergic disease. Diseases, record MONDO_0005271. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005271

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: allergic disease; Open Targets
Open Targets ID: MONDO_0005271; Open Targets
Other names: Allergic Reactions, Allergies, Hypersensitivities, Reaction, Allergic, Reactions, Allergic, allergic disease or disorder, allergic form of disease or disorder, allergic form of immune system disease, allergic reaction, allergic response, allergy, disorder of type I hypersensitivity, hypersensitivity, hypersensitivity reaction type I disease, type I hypersensitivity disease; Open Targets
Disease Ontology: DOID:1205; Disease Ontology
MeSH: D006967; MeSH
NCI Thesaurus: C114476; NCI Thesaurus
Highest stage of its drugs: Approval, for 75 of its 91 drugs, from ATC and DailyMed; Open Targets

Drugs91

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CETIRIZINE	CHEMBL1000	Small molecule	Approval	ATC	3	2	2	Drugs and targets
LEVOCETIRIZINE	CHEMBL1201191	Small molecule	Approval	ATC	3	2	2	Drugs and targets
EPINEPHRINE	CHEMBL679	Small molecule	Approval	DailyMed	8	1	1	Drugs and targets
DESLORATADINE	CHEMBL1172	Small molecule	Approval	ATC	2	1	1	Drugs and targets
CHLORPHENIRAMINE MALEATE	CHEMBL1659	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
BROMPHENIRAMINE	CHEMBL811	Small molecule	Approval	ATC	2	0	0	Drugs and targets
BUCLIZINE	CHEMBL1201271	Small molecule	Approval	ATC	2	0	0	Drugs and targets
CHLOROPYRAMINE	CHEMBL1194287	Small molecule	Approval	ATC	2	0	0	Drugs and targets
CHLORPHENIRAMINE	CHEMBL505	Small molecule	Approval	ATC	2	0	0	Drugs and targets
CHLORPHENOXAMINE	CHEMBL2110774	Small molecule	Approval	ATC	2	0	0	Drugs and targets

1 to 10 of 91

See all 91 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH1	Histamine H1 receptor	49	Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
ADRA1A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01831817	Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity	Phase 2	140	2015-03-26	Dentinal Hypersensitivity	CALCIUM SODIUM PHOSPHOSILICATE, SODIUM FLUORIDE, SODIUM MONOFLUOROPHOSPHATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04249336	Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH	Phase 3	140	2021-05-11	Dentin Hypersensitivity	ARGININE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02237196	Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy	Phase 1/2	121	2020-05-06	Cat Allergy, Cat Hypersensitivity	TEZEPELUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00359138	The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)	Phase 4	36	2010-11-01	Hypersensitivity	DESLORATADINE, LEVOCETIRIZINE	Its record names the disease	ClinicalTrials.gov
NCT00826943	Is Levocetirizine Less Sedating Than Cetirizine?	Phase 4	30	2014-02-20	Allergic Rhinitis	CETIRIZINE, LEVOCETIRIZINE	Its record names the disease	ClinicalTrials.gov
NCT01003301	The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge	Phase 2	19	2014-04-07	Cat Allergy	OMALIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT06834165	Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy	Phase 4	600		Allergic Reactions	EPINEPHRINE	Its record names the disease	ClinicalTrials.gov
NCT05061524	A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases	Phase 1	68		Atopic Healthy Subjects, Adult Subjects with Mild Allergic Diseases	OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04819867	Comparison Of The Effect Of Propolis And Gluma Desensitizer On The Management Of Dentin Hypersensitivity	Phase 2/3	40		Dentin Hypersensitivity	GLUTARAL, PROPOLIS WAX	Open Targets' reading of its record	ClinicalTrials.gov
NCT01322282	To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy	Phase 1	36		Allergy	CETIRIZINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Omalizumab vs Placebo: serious adverse events	0 of 10	0 of 9	19	NCT01003301

Source Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38783427	DERIVED	1	PubMed
36223848	DERIVED	1	PubMed
34615511	DERIVED	1	PubMed
23791510	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005271

GET https://conductscience.org/api/diseases/v1/MONDO_0005271/drugs?page=2

API reference For AI assistants